Thus, the compromised cytotoxicity of CD8+ T cells together with the heterogeneity of tumor cell intrinsic mutations are major obstacles to improve the therapeutic efficacy of checkpoint inhibitors in GBM. Here, CD8A is linked to glioblastoma.